研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

一项关于68Ga-LNC1007和2-18F-FDG/68Ga-FAPI-02 PET/CT在不同癌症患者中的直接比较。

A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.

发表日期:2023 Oct 01
作者: Jie Zang, Rong Lin, Xuejun Wen, Chao Wang, Tianzhi Zhao, Vivianne Jakobsson, Yun Yang, Xiaoming Wu, Zhide Guo, Xiaoyuan Chen, Jingjing Zhang, Weibing Miao
来源: MOLECULAR & CELLULAR PROTEOMICS

摘要:

本研究旨在进行头对头的比较研究,探究68Ga-LNC1007放射性示踪剂在检测各类癌症患者的原发病灶和转移病灶时的摄取情况和临床可行性,并将结果与2-18F-FDG PET/CT和68Ga-FAPI-02 PET/CT进行比较。本研究纳入了61例不同类型癌症患者,其中50例患者接受了配对的68Ga-LNC1007和2-18F-FDG PET/CT检查,另外11例患者接受了配对的68Ga-LNC1007和68Ga-FAPI-02 PET/CT检查。最终诊断基于组织病理学结果和诊断影像学。对于24例原发肿瘤进行了FAP和整合素αvβ3的免疫组化检测。68Ga-LNC1007 PET/CT对所有55例原发肿瘤均具有检测能力,而2-18F-FDG PET/CT对45例原发肿瘤呈可视阳性(P = 0.002)。此外,亚组分析显示,在诊断肾细胞癌和肝细胞癌方面,68Ga-LNC1007 PET/CT优于2-18F-FDG PET/CT。对于转移性肿瘤而言,与2-18F-FDG相比,68Ga-LNC1007 PET/CT对骨转移和腹膜转移显示更多PET阳性病灶和更高的SUVmax。68Ga-LNC1007 PET/CT上的原发肿瘤SUVmax和肿瘤与背景之比均高于68Ga-FAPI-02 PET/CT,转移性肿瘤亦有相同结果。免疫组织化学结果显示,68Ga-LNC1007 PET测得的SUVmean与FAP表达水平相关(r = 0.564,P = 0.005)。68Ga-LNC1007是一种有希望的新型诊断PET示踪剂,可用于影像学检测各种恶性病变。它可能是诊断肾细胞癌、肝细胞癌、骨转移和腹膜转移的较好选择,比2-18F-FDG更为理想。版权所有© 2023 Wolters Kluwer Health, Inc. 保留所有权利。
This head-to-head comparison study was designed to investigate the radiotracer uptake and clinical feasibility of using 68Ga-LNC1007, to detect the primary and metastatic lesions in patients with various types of cancer, and to compare the results with those of 2-18F-FDG PET/CT and 68Ga-FAPI-02 PET/CT.Sixty-one patients with 10 different kinds of cancers were enrolled in this study. Among them, 50 patients underwent paired 68Ga-LNC1007 and 2-18F-FDG PET/CT, and the other 11 patients underwent paired 68Ga-LNC1007 and 68Ga-FAPI-02 PET/CT. The final diagnosis was based on histopathological results and diagnostic radiology. Immunohistochemistry for FAP and integrin αvβ3 was performed in 24 primary tumors.68Ga-LNC1007 PET/CT detected all 55 primary tumors, whereas 2-18F-FDG PET/CT was visually positive for 45 primary tumors (P = 0.002). Furthermore, subgroup analysis showed that 68Ga-LNC1007 PET/CT was superior to 2-18F-FDG PET/CT in diagnosing renal cell carcinomas and hepatocellular carcinomas. For metastatic tumors, 68Ga-LNC1007 PET/CT revealed more PET-positive lesions and higher SUVmax for skeletal metastases and peritoneal metastases compared with 2-18F-FDG. The SUVmax and tumor-to-background ratio of primary tumors on 68Ga-LNC1007 PET/CT were much higher than those on 68Ga-FAPI-02 PET/CT, the same was also observed for metastatic tumors. Immunohistochemical results showed that the SUVmean quantified from 68Ga-LNC1007 PET was correlated with FAP expression level (r = 0.564, P = 0.005).68Ga-LNC1007 is a promising new diagnostic PET tracer for imaging of various kinds of malignant lesions. It may be a better alternative to 2-18F-FDG for diagnosing renal cell carcinoma, hepatocellular carcinoma, skeletal metastases, and peritoneal metastases.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.